TransMedics Group (NASDAQ:TMDX) PT Raised to $117.00 at Canaccord Genuity Group

TransMedics Group (NASDAQ:TMDX) had its price objective upped by equities research analysts at Canaccord Genuity Group from $102.00 to $117.00 in a report released on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would indicate a potential downside of 5.98% from the stock’s current price.

A number of other analysts have also commented on TMDX. Oppenheimer boosted their price target on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a report on Wednesday. Morgan Stanley boosted their price target on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. Piper Sandler reiterated an “overweight” rating and set a $120.00 target price (up previously from $95.00) on shares of TransMedics Group in a report on Wednesday. Finally, JPMorgan Chase & Co. upped their target price on TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $119.00.

TransMedics Group Stock Up 5.8 %

NASDAQ:TMDX opened at $124.44 on Wednesday. TransMedics Group has a 1 year low of $36.42 and a 1 year high of $124.52. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49. The stock has a 50-day moving average price of $84.64 and a two-hundred day moving average price of $76.26.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. The company had revenue of $96.90 million for the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The company’s quarterly revenue was up 132.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.08) earnings per share. As a group, sell-side analysts expect that TransMedics Group will post -0.14 EPS for the current year.

Insiders Place Their Bets

In other TransMedics Group news, Director Edward M. Basile sold 7,157 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $86.38, for a total transaction of $618,221.66. Following the transaction, the director now owns 8,350 shares of the company’s stock, valued at $721,273. The sale was disclosed in a document filed with the SEC, which is available through this link. In other TransMedics Group news, insider Tamer I. Khayal sold 776 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $90.00, for a total transaction of $69,840.00. Following the transaction, the insider now owns 14,375 shares of the company’s stock, valued at $1,293,750. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Edward M. Basile sold 7,157 shares of the company’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $86.38, for a total value of $618,221.66. Following the completion of the transaction, the director now directly owns 8,350 shares in the company, valued at approximately $721,273. The disclosure for this sale can be found here. Insiders have sold a total of 102,078 shares of company stock valued at $8,691,221 over the last 90 days. 7.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC grew its position in shares of TransMedics Group by 42.5% in the third quarter. FMR LLC now owns 4,714,870 shares of the company’s stock valued at $258,139,000 after purchasing an additional 1,407,171 shares during the last quarter. Vanguard Group Inc. increased its stake in TransMedics Group by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock worth $147,214,000 after acquiring an additional 50,673 shares during the period. Eventide Asset Management LLC increased its stake in TransMedics Group by 7.4% during the 4th quarter. Eventide Asset Management LLC now owns 994,240 shares of the company’s stock worth $78,475,000 after acquiring an additional 68,884 shares during the period. Sandhill Capital Partners LLC increased its stake in TransMedics Group by 4.2% during the 4th quarter. Sandhill Capital Partners LLC now owns 763,201 shares of the company’s stock worth $60,239,000 after acquiring an additional 30,591 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of TransMedics Group by 91.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock valued at $41,615,000 after purchasing an additional 363,012 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.